Question-and-Answer SessionCatherine SzymanCEO & Director Yes. I mean, first of all, the vision for Masimo is that we want to be the world leader in patient monitoring, right? And so I think if you look at the patient monitoring space, there's still room for growth. And where I see the biggest growth opportunity is just to transform patient care by actually getting patients to be monitored from the minute they hit the curb of the hospital to the minute they leave. And right now, I think patients believe tha ...

Masimo (MASI) FY 2025 Conference September 04, 2025 01:30 PM ET Company ParticipantsMicah Young - EVP & CFOKatie Szyman - CEO & DirectorConference Call ParticipantsVik Chopra - Equity Research AnalystVik ChopraGood afternoon, everyone. My name is Vivek Chopra. I am on the Medical Device Equity Research team here at Wells Fargo. I'm happy to announce management from Masimo for this session. Joining us for the company are Katie Szyman, CEO, and Micah Young, VP and CFO. Thank you both for being here.Micah Youn ...

Masimo (MASI) FY 2025 Conference September 04, 2025 01:30 PM ET Speaker0Good afternoon, everyone. My name is Vivek Chopra. I am on the Medical Device Equity Research team here at Wells Fargo. I'm happy to announce management from Masimo for this session. Joining us for the company are Katie Szyman, CEO, and Micah Young, VP and CFO. Thank you both for being here.Speaker2Thank you, Vivek.Thank you.Speaker0Katie, maybe starting off with you, a few big-picture questions. You've been CEO since the beginning of t ...

Core Viewpoint - The ongoing patent dispute between Apple and Masimo has intensified, particularly following the reintroduction of blood oxygen monitoring features in the Apple Watch, which has led to legal actions involving the U.S. government [1][9]. Group 1: Background of the Patent Dispute - Masimo, a leader in the field of vital sign monitoring, has been engaged in a long-standing patent battle with Apple since 2013, when Apple sought to develop health monitoring features for its wearable devices [1][2]. - The conflict escalated when key Masimo employees, including a significant technical talent, transitioned to Apple, leading to allegations of patent infringement by Masimo [2][3]. Group 2: Legal Proceedings and Outcomes - In January 2020, Masimo filed a lawsuit against Apple for infringing on multiple patents related to pulse oximetry technology, which was followed by Apple's counteractions to invalidate Masimo's patents [3][5]. - A significant ruling in April 2023 favored Apple, with a jury siding with the company, but the legal battles continued as Masimo expanded its claims to include newer Apple Watch models [3][8]. Group 3: Recent Developments - In October 2023, the ITC ruled that Apple had infringed on Masimo's patents, resulting in an import ban on certain Apple Watch models, prompting Apple to suspend sales of these products in the U.S. [8][9]. - Apple managed to restore the blood oxygen monitoring feature through a software update that shifted the processing to paired iPhones, circumventing the ITC's ban [8][9]. Group 4: Implications for the Industry - The outcome of this patent dispute could have significant implications for domestic wearable health device companies, particularly as blood oxygen monitoring becomes a critical feature in health tech [10]. - While the current legal issues primarily affect the U.S. market, there is a potential risk for domestic companies looking to expand internationally, necessitating careful patent strategy and risk assessment [10][11].

Core Viewpoint - The legal dispute between Masimo and Apple centers around the blood oxygen functionality in Apple Watches, with Masimo alleging that U.S. Customs and Border Protection (CBP) improperly allowed Apple to import watches equipped with pulse oximeter technology without consulting Masimo [1][3]. Group 1: Legal Dispute - Masimo has filed a lawsuit against CBP in federal court, claiming that the agency reversed its previous decision regarding the importation of Apple Watches with blood oxygen reading capabilities without notifying Masimo [3]. - The conflict between Masimo and Apple has been ongoing, with Masimo accusing Apple of poaching its employees and stealing technology for the pulse oximeter used in Apple Watches [3]. - In 2023, Masimo successfully convinced the U.S. International Trade Commission (ITC) to block the import of Apple Series 9 and Ultra 2 smartwatches due to patent infringement related to blood oxygen level reading technology [3]. Group 2: Recent Developments - On August 14, Apple announced it would reintroduce the blood oxygen reading feature in its smartwatches, contingent upon CBP's approval, which Masimo argues was granted without proper consultation [3]. - Masimo contends that CBP's actions undermine its rights and responsibilities, emphasizing that the agency should enforce the ITC's exclusion order rather than create loopholes [3]. - Masimo is seeking a court order to halt CBP's decision and prevent Apple from selling watches with blood oxygen functionality [3].

Core Points - Masimo has filed a lawsuit against the U.S. Customs and Border Protection (CBP), alleging that CBP unlawfully allowed Apple to reinstate a blood oxygen monitoring feature on the Apple Watch that infringes on Masimo's patents [1] - The dispute stems from a 2023 ruling by the U.S. International Trade Commission, which found Apple guilty of patent infringement, leading to a suspension of certain Apple Watch sales [1] - On August 14, Apple announced a software update to restore the blood oxygen monitoring feature by shifting the calculation process to the paired iPhone instead of the watch itself [1] - Masimo claims it was unaware of CBP's unilateral decision made two weeks prior, which overturned an earlier ruling without consulting Masimo, violating standard procedures [1] - The lawsuit cites violations of the Administrative Procedure Act and the due process clause of the Fifth Amendment [1] Legal Actions - Masimo is seeking a temporary restraining order and a preliminary injunction to prevent the enforcement of CBP's August 1 ruling [2] - The company aims to restore the January decision, which was made with participation from both Apple and Masimo, stipulating that related products could only be imported if the blood oxygen monitoring feature was disabled [2]

Core Insights - Masimo (MASI) received FDA 510(k) clearance for expanded indications of its O3 Regional Oximetry, which now includes delta hemoglobin parameters to track changes in hemoglobin levels, enhancing the ability to identify causes of tissue oxygen saturation shifts [1][6] - The O3 platform, built on Masimo's Root platform, utilizes near-infrared spectroscopy to measure continuous regional oxygen saturation (rSO2), providing deeper insights into oxygen imbalances and aiding precise clinical interventions [2][7] - The FDA approval broadens the clinical utility of O3 across all patient populations, including pediatrics and neonates, making it more valuable in critical care settings [4][8] Company Performance - Following the FDA announcement, MASI shares declined by 4.6% at market close, with a year-to-date loss of 11.2%, compared to the industry decline of 7.6% and a 9.5% gain in the S&P 500 [3] - Masimo currently has a market capitalization of $8.36 million and reported an earnings surprise of 8.13% in the last quarter [5] Industry Outlook - The FDA clearance is expected to act as a growth catalyst for Masimo by enhancing the adoption of its O3 platform and driving recurring revenue from monitoring solutions, positioning the company to capture a larger share of the high-margin brain and tissue monitoring market [4] - The global cerebral oximetry monitoring market was valued at $239.4 million in 2024 and is projected to grow at a CAGR of 6.7% from 2025 to 2034, driven by the increasing prevalence of neurological ailments and surgeries [10]

医疗监测技术公司马西莫医疗(MASI.US)跌超4.3%，报149.14美元。消息面上，苹果表示，在获得美国 政府批准后，将通过软件更新推送血氧测量功能。美国的Apple Watch Series 9、Series 10和Apple Watch Ultra 2用户现在可以在配对的 iPhone上查看自己的血氧水平。(格隆汇) ...

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, particularly in the financial sector, to achieve exceptional returns. However, identifying such stocks can be challenging due to inherent volatility and risks associated with growth stocks [1]. Group 1: Company Overview - Masimo (MASI) is highlighted as a recommended growth stock due to its favorable Growth Score and top Zacks Rank [2]. - The company has a historical EPS growth rate of 2.5%, but projected EPS growth for the current year is expected to be 14.6%, surpassing the industry average of 12.4% [4]. Group 2: Financial Metrics - Cash flow growth is crucial for growth-oriented companies, and Masimo currently exhibits a year-over-year cash flow growth of 13%, significantly higher than the industry average of -2.6% [5]. - Over the past 3-5 years, Masimo's annualized cash flow growth rate has been 10.7%, compared to the industry average of 6.3% [6]. Group 3: Earnings Estimates - Positive trends in earnings estimate revisions are important, and Masimo has seen a 6.9% increase in current-year earnings estimates over the past month [7]. - The combination of a Growth Score of A and a Zacks Rank of 2 positions Masimo favorably for potential outperformance in the market [8].

Core Insights - Masimo Corporation (MASI) reported adjusted earnings per share (EPS) of $1.33 for Q2 2025, reflecting a 46.2% year-over-year increase and surpassing the Zacks Consensus Estimate by 8.1% [1] - The company's revenues reached $370.9 million in Q2 2025, marking a 7.9% year-over-year growth and exceeding the Zacks Consensus Estimate by 0.6% [2] - Masimo's gross profit increased by 12.5% year-over-year to $233.3 million, with a gross margin expansion of 262 basis points to 62.9% [6] Revenue Breakdown - Revenue excluding related party revenues was $345.1 million, up 8.2% year-over-year, while related party revenues were $25.8 million, up 2.8% year-over-year [4] - Healthcare revenues totaled $370.3 million, reflecting a 7.7% increase on a reported basis and 7.4% at constant exchange rates [5] - Consumable and service revenues within the Healthcare segment grew by 8.4%, while capital equipment and other revenues declined by 2% year-over-year [5] Margin and Expense Analysis - Adjusted operating profit for Q2 was $64.5 million, a 53.9% increase from the previous year, with an adjusted operating margin expansion of 521 basis points to 17.4% [8] - Selling, general, and administrative expenses rose by 9.9% year-over-year to $138.9 million, while research and development expenses decreased by 23.5% to $29.9 million [8] Financial Position - At the end of Q2 2025, Masimo had cash and cash equivalents of $149.6 million, up from $130.8 million at the end of Q1 2025, and long-term debt decreased to $598.7 million from $636 million [9] - Cumulative net cash provided by operating activities from continuing operations was $99.5 million, compared to $106 million a year ago [9] Guidance and Outlook - Masimo has raised its revenue outlook for 2025 to a range of $1,505 million to $1,535 million, reflecting an 8-11% increase at constant exchange rates from 2024 [10] - Adjusted EPS for 2025 is now projected to be between $5.45 and $5.70, indicating a growth of 30-36% from 2024 figures [11] Overall Assessment - The company demonstrated strong performance in Q2 2025 with better-than-expected results, particularly in Healthcare revenues and margin expansion [12] - However, lower capital equipment and other revenues were noted as a downside [13]